Prabhudas Lilladher's research report on Lupin
Lupin’s (LPC) Q2FY26 EBITDA stood at Rs21.4bn 20% beat to our estimates on the back of higher US sales supported by niche launches like gTolvaptan. LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23- 24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY27E and FY28E EPS broadly remain unchanged.
Outlook
We maintain BUY rating with TP of Rs 2,400 (24x Sept 2027E EPS). Any competition in gSpiriva and delay in new launches in the US will be key risks to our estimates.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
